This highly anticipated panel discussion provides attendees an exclusive opportunity to hear firsthand from three outstanding leaders in the field. Drs. Harvey J. Alter, Michael Houghton, and Charles M. Rice, the 2020 recipients of the Nobel Prize in Physiology or Medicine, will join TLMdX LIVE for a question and answer session. Their groundbreaking research identified the Hepatitis C virus (HCV) a bloodborne pathogen that causes acute and chronic hepatitis, cirrhosis, and liver cancer and laid the foundation for the future development of a cure.

Don’t overlook any of the research presented at TLMdX that directly impacts patients. New this year, an patient advocate will briefly review of all the abstracts presented at the meeting that significantly impacted the role of the patient in one condensed session.

The COVID-19 patient engagement subcommittee presents patient-centered updates on the current knowledge, practice and recommendations in the care of chronic liver disease in the COVID-19 era at this timely session. Presentations include current data on COVID-19 and the liver, patient-driven case studies, and case discussions of liver disease patients who have recovered from COVID-19.

Non-alcoholic fatty liver disease (NAFLD) is not rare among lean individuals. But in the absence of traditional risk factors, it remains under-recognized. At this JSH-AASLD session, experts unravel the latest data on lean-NASH prevalence in the general population. Speakers will also explore the influence of genetics and environment, and the impact of metabolic abnormalities in fibrosis development in lean-NASH.

This workshop explores laboratory-based and clinical research methodologies using alcohol-associated liver disease as a model. Experts will share strategies to identify mechanisms of hepatocyte injury and fibrosis and biomarkers for alcohol-associated injury, and discuss viable techniques for developing prediction models, qualitative research methodologies and how to design clinical trials and endpoints using large demonstrated databases.

Explore timely topics in liver disease in a lively debate format as pediatric and adult/general hepatology trainees and practicing hepatologists tackle important, often controversial issues. Debaters will gain skills in critical thinking, balanced argumentation and factual examination of each issue's pros and cons. Debaters, judges and audience members will grapple with opposing scientific, societal, individual and financial viewpoints on current clinical concerns. 

Children's Hospital of Philadelphia vs Children's Hospital Colorado 

Emcee: Nancy Reau Panelists: Emily R. Perito, Rohit Kohli, John Bucuvalas 

Children's Hospital of Philadelphia FELLOWS: Taisa Kohut and Tamir Diamond MENTOR: Elizabeth Rand 

Children's Hospital Colorado FELLOWS: Sarah Kemme and Julia Boster MENTOR: Amy Feldman

The global pandemic has affected patients with liver disease in unexpected ways. At this symposium, faculty review the effects of COVID-19 on the liver and how people with liver disease differ in their responses to COVID-19. They will review the latest data on COVID-19 treatments, COVID-19 prevention strategies including vaccines, and racial disparities revealed by this unprecedented epidemic.

What role does social media, the communications landscape that currently influences everything from politics to pop culture, play in hepatology and healthcare? This program will expose participants to different aspects of social media and encourage discussion ways that social media could advance the science and practice of hepatology.

This two-session program explores non-cirrhotic portal hypertension in both children and adults. The first session covers the definition/nomenclature and diagnostic strategies for non-cirrhotic portal hypertension. The second session explores monitoring and management of children and adults with non-cirrhotic portal hypertension, including medical, interventional radiology, and surgical challenges. Each session includes case presentations to highlight controversies, expert panel interviews and Q&A.

The practice of hepatology has undergone profound shifts driven by new pathophysiologic insights which, in many cases, force us to rethink traditional medical dogma. This is also an era of profound progress in diagnostics and therapeutics. This program explores these seismic shifts to allow attendees to re-energize their practices, and embrace new goals and objectives for treating many liver diseases.